This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "orexin_arousal_instability#Sleep-Wake State Instability", the key conformance target and rate-limiting step).
WHAT CONFORMANCE REQUIRES. Entry at the trigger node requires evidence of an orexin-system lesion in that disorder - CSF hypocretin-1 deficiency, postmortem orexin neuron loss, or a causal HCRT/HCRTR variant. Hypersomnolence alone is NOT sufficient and must not be conformed here. This boundary is the main thing the module is for, and two negative cases are load-bearing:
(1) Idiopathic hypersomnia does NOT conform. Its patients have normal CSF hypocretin-1 by definition, and the leading candidate mechanism runs the other way - a CSF substance that potentiates GABA-A signalling, i.e. excess somnogenic inhibition rather than deficient orexinergic excitation. An idiopathic hypersomnia entry may cite this module for contrast but must not declare conformance.
(2) Narcolepsy type 2 (narcolepsy without cataplexy) does NOT conform at the trigger node. CSF hypocretin-1 is normal or intermediate in most such patients, and whether NT2 is even a distinct entity from idiopathic hypersomnia is unsettled. An NT2 entry may conform at #Sleep-Wake State Instability and #Dissociated Intrusion of REM Sleep Components into Wakefulness if it evidences sleep-onset REM periods, but the orexin-deficiency trigger is a claim it cannot make.
DRUG-TARGET PATTERN - BIDIRECTIONAL, on the same amplifier node. Orexin receptor 2 agonists (oveporexton/TAK-861) ACTIVATE #Orexin Receptor Signalling Deficiency at Ascending Arousal Nuclei, restoring the missing drive; dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) INHIBIT the same node to produce sleep in insomnia. The two arms are the same pharmacology read in opposite directions and are the clearest demonstration that this node is rate-limiting for wakefulness. Neither is a treatment recommendation inherited by conforming disorders: a DORA is contraindicated in narcolepsy, and an OX2R agonist would be expected to worsen insomnia.
SCOPE BOUNDARIES. This module covers the ORIGIN of state instability in the orexin system. It deliberately does NOT re-derive the pontine REM-atonia circuitry that executes cataplexy and REM sleep behaviour disorder - that is rem_sleep_atonia_control_failure, and the relationship is worth stating precisely: cataplexy is REM atonia machinery intruding into wakefulness, while REM sleep behaviour disorder is that same machinery failing during REM sleep. They are opposite failures of one circuit, and a narcolepsy type 1 entry that curates both should conform to both modules rather than blending them. The module is also distinct from circadian_phase_misalignment (where sleep is normal but mistimed) and from sleep_disordered_breathing_intermittent_hypoxia (where sleepiness follows fragmentation by respiratory events, with an intact orexin system).
Not an Xogenesis module - a normal stabilising signal is lost, nothing pathological is formed.
Does restoring orexin receptor signalling pharmacologically reproduce physiological orexin function, or only its wake-promoting arm?
KNOWLEDGE GAP
gap_tonic_vs_patterned_ox2r_agonism
Attached to:
Orexin Receptor Signalling Deficiency at Ascending Arousal Nuclei
Endogenous orexin neurons fire in a state- and context-dependent pattern and also carry autonomic, feeding, and reward-related signals. A continuously present oral agonist supplies tonic rather than patterned drive, and the commonest adverse events reported in the phase 2 trial - insomnia, urinary urgency, and urinary frequency - are plausibly the signature of that mismatch rather than off-target toxicity. Whether tonic OX2R agonism restores the module's central_effector node (state stability) or merely raises wake drive is unresolved, and it matters: the two predict different long-term effects on nocturnal sleep architecture.
Proposed experiments:
Polysomnographic architecture under sustained OX2R agonism
Loss of Hypothalamic Orexin (Hypocretin) Signal
trigger
The shared initiating lesion is loss of the orexin peptide signal originating from the lateral hypothalamic area. In the common human form this is destruction of the orexin-producing neurons themselves: postmortem series show an 85-95% reduction in orexin neuron number, and the loss is cell-type-selective - the intermingled melanin-concentrating hormone neurons are spared, which excludes a nonspecific hypothalamic lesion. Because the population is small and unreplaced, the deficit is permanent and is detectable in life as low or undetectable CSF hypocretin-1. Conforming disorder nodes substitute the disorder-specific route to this lesion: immune-mediated neuron destruction (narcolepsy type 1), a preprohypocretin (HCRT) coding mutation impairing peptide trafficking and processing (the rare monogenic form), or a structural, inflammatory, or infiltrative hypothalamic lesion (secondary/symptomatic narcolepsy).
Downstream
-
Orexin Receptor Signalling Deficiency at Ascending Arousal Nuclei
Loss of the orexin peptide removes the ligand for OX1R and OX2R on the ascending arousal nuclei that orexin neurons innervate.
Show evidence (4 references)
"human narcoleptics have an 85%-95% reduction in the number of Hcrt neurons"
Quantifies the trigger lesion in human postmortem hypothalamus and fixes its magnitude, which is why the deficit behaves as an all-or-none loss of signal rather than a graded reduction.
"Melanin-concentrating hormone (MCH) neurons, which are intermixed with Hcrt cells in the normal brain, are not reduced in number, indicating that cell loss is relatively specific for Hcrt neurons"
Establishes cell-type selectivity, which is what makes this a defined module trigger rather than a generic hypothalamic injury; a conforming disorder claiming this node should be able to show comparable specificity.
"One Hcrt mutation, impairing peptide trafficking and processing, was found in a single case with early onset narcolepsy."
Documents the monogenic substitution at this node - a peptide-side coding lesion producing the same loss of signal as neuronal destruction, which is the evidence that the trigger is the signal rather than the cell.
+ 1 more reference
Orexin Receptor Signalling Deficiency at Ascending Arousal Nuclei
amplifier
Orexin neurons project widely to the monoaminergic and cholinergic arousal nuclei and excite them through OX1R and OX2R. Loss of that excitatory drive - whether from absent ligand (the human disease) or absent receptor (the canine model) - produces the same phenotype, which localises the rate-limiting step to receptor-level signalling rather than to the peptide or the neuron. OX2R carries most of the wake-stabilising signal, which is why the receptor subtype rather than the cell is the drug target.
Downstream
-
Sleep-Wake State Instability
Without orexinergic excitation the arousal nuclei can no longer be held above the threshold that keeps the sleep-wake switch in a stable position, so the switch flips at inappropriate times in both directions.
Show evidence (3 references)
"canine narcolepsy is caused by disruption of the hypocretin (orexin) receptor 2 gene (Hcrtr2)"
Receptor-side loss reproduces the full syndrome, which is the evidence that this node - not the peptide or the neuron - is where the causal chain is rate-limited, and is why the module places the drug target here.
"orexin knockout mice exhibit a phenotype strikingly similar to human narcolepsy patients"
Ligand-side genetic loss converges on the same phenotype as receptor-side loss, closing the ligand-receptor argument for this node.
"Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain."
States the receptor-level deficit that the OX2R agonist arm of the drug pattern is designed to reverse.
Sleep-Wake State Instability
central effector
The rate-limiting, disorder-agnostic node and the key conformance target. Loss of orexinergic stabilisation does not abolish any single behavioural state; it makes every state transition too easy. Wakefulness fragments into involuntary sleep episodes, and nocturnal sleep fragments into frequent awakenings - which is why patients are both excessively sleepy by day and poor sleepers by night, an apparent paradox that this node explains and that a purely "insufficient wake drive" model does not. A conforming disorder node should evidence instability in both directions, not only daytime sleepiness.
Downstream
-
Dissociated Intrusion of REM Sleep Components into Wakefulness
An unstable switch permits REM sleep to be entered directly from wakefulness and permits individual REM components to appear in isolation, dissociated from the rest of the state.
Show evidence (2 references)
"We propose that orexin regulates sleep/wakefulness states"
Names the function lost at this node - regulation of state rather than production of wakefulness - which is the distinction the module turns on.
"It is characterized by daytime sleepiness, cataplexy, and striking transitions from wakefulness into rapid eye movement (REM) sleep."
Describes the instability phenotype as abrupt inappropriate state transitions, which is the readout a conforming node needs.
Dissociated Intrusion of REM Sleep Components into Wakefulness
effector
REM sleep is normally an all-or-none package: EEG desynchronisation, rapid eye movements, dreaming, and skeletal muscle atonia arrive together. State instability lets the package come apart, so single components appear at the wrong time and without the others. Muscle atonia intruding into full wakefulness is cataplexy; atonia persisting into waking consciousness at a state boundary is sleep paralysis; dream imagery without sleep is hypnagogic hallucination; and the whole state entered directly from wake is a sleep-onset REM period. This node is what distinguishes orexin-driven hypersomnolence from every other cause of sleepiness, and is the diagnostic signature a conforming entry should evidence.
Used by disorders
Narcolepsy
as Dissociated Intrusion of REM Sleep Components
Downstream
-
Hypersomnolence with REM Dissociation Syndrome
The combination of an unstable switch and dissociated REM components produces the clinical syndrome.
Show evidence (2 references)
"This result identifies hypocretins as major sleep-modulating neurotransmitters"
Places the REM-dissociation phenotype downstream of hypocretin neurotransmission rather than treating it as an independent finding.
"a disorder characterized primarily by rapid eye movement (REM) sleep dysregulation"
Identifies REM dysregulation as the defining downstream consequence of orexin loss, which is what this node models.
Hypersomnolence with REM Dissociation Syndrome
consequence
The clinical endpoint: irrepressible daytime sleepiness with short sleep latency and sleep-onset REM periods, together with some combination of cataplexy, sleep paralysis, hypnagogic hallucination, and fragmented nocturnal sleep. The syndrome is lifelong and non-progressive, because the trigger lesion is a completed loss rather than an ongoing degeneration - a prognostic point conforming entries should preserve.
Show evidence (2 references)
"Narcolepsy-cataplexy with hypocretin deficiency is a genuine disease entity."
Establishes that the hypocretin-deficient syndrome is a distinct entity rather than a severity band of hypersomnolence generally, which is the claim the conformance boundary in the module notes rests on.
"Healthy controls and subjects with other sleep disorders all had normal levels."
Supports the negative boundary stated in the notes: other sleep disorders, including other hypersomnias, do not share this trigger and must not conform to it.
Orexin Receptor 2-Selective Agonist (Oveporexton)
Platform:
Small molecule
Oveporexton (TAK-861) is an oral small-molecule agonist selective for the orexin receptor 2. It supplies the missing receptor-level drive directly, bypassing the irreversibly lost orexin neurons, and is the positive arm of this module's bidirectional drug-target pattern. In a phase 2 trial in narcolepsy type 1 it improved objective wakefulness, subjective sleepiness, and cataplexy rate together - which is mechanistically informative, because a single receptor-level intervention correcting all three confirms that they share one upstream node. This is a mechanism pattern, not a treatment recommendation inherited by conforming disorders; a disorder without an orexin-signalling deficit has no reason to respond.
Evidence: 1
Dual Orexin Receptor Antagonist (Suvorexant)
Platform:
Small molecule
The negative arm of the same drug-target pattern, and the reason the module's amplifier node is best understood as a rheostat rather than a switch. Suvorexant and the other dual orexin receptor antagonists block OX1R and OX2R to reduce arousal drive and produce sleep in insomnia - pharmacologically inducing, in a controlled and reversible way, the same receptor-level deficit that the trigger node produces permanently. Curated here for mechanistic symmetry only: a DORA is contraindicated in narcolepsy, and conforming disorders do not inherit it as a treatment.
Evidence: 1